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ing type 2 diabetes (T2D) by 58% and 31% respectively,
vs. controls. A model was developed to explore the long-
term cost-effectiveness of DPP interventions in France,
Germany, and UK. METHODS: A Markov model simu-
lated 3 states: “IGT”, “T2D”, and “dead”. Probabilities
were derived from DPP and published mortality data. 
Life expectancy (LE) was calculated for each treat-
ment arm. Country-speciﬁc direct costs were retrieved
from published sources. Lifetime costs/patient (TC) were 
calculated. Incremental cost-effectiveness ratios were 
calculated (costs/life-year gained [C/LYG]). (TC and LE
discounted 5% p.a.). Extensive sensitivity analysis was
performed to identify parameters with important impacts
on outcomes. RESULTS: Time to onset of diabetes was
8.27, 14.44, and 10.76 years for placebo, ILC, or met-
formin respectively. Delaying the onset of T2D with either
ILC or MET improved discounted LE vs. placebo by 0.19
and 0.08 years respectively. ILC lead to TC increases vs.
placebo of €2958, 1365, and 1707/patient for France,
Germany and UK respectively; and for MET increases vs.
placebo of €636, 374, and 316/patient for France,
Germany and UK respectively. C/LYG were: France—ILC
vs. placebo €15,568 and MET vs. placebo €7,950;
Germany—ILC vs. placebo €7,184 and MET vs. placebo
€4,675; and UK—ILC vs. placebo €8,984 and MET vs.
placebo €3,950. Results were most sensitive to the prob-
abilities of developing T2D, the relative risk of mortality
for the state T2D compared to IGT, and the costs of
implementing the DPP. CONCLUSIONS: ILC and MET
delayed diabetes onset and lead to improvements in LE.
Both ILC and MET were highly cost-effective in all 3
countries (i.e. C/LYG < €28,000).
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OBJECTIVES: The Irbesartan in Diabetic Nephropathy
Trial (IDNT) demonstrated a 20% and 23% reduction
compared to no treatment or amlodipine respectively in
the combined endpoint of doubling of serum creatinine
(DSC), end-stage renal disease (ESRD) or death in
patients with hypertension (treated with all antihyperten-
sive drugs except ACE-inhibitors and Ca-antagonists),
type 2 diabetes and overt nephropathy (H-T2DM-N). A
simulation model was developed to project the long-term
cost-consequences of the IDNT in Belgium and France.
METHODS: A Markov model simulated progression
from nephropathy to DSC, ESRD, death, and cardiovas-
cular events in H-T2DM-N treated with irbesartan,
amlodipine, or placebo. Treatment-speciﬁc probabilities
were derived from IDNT. Country-speciﬁc ESRD-related
transition probabilities were retrieved to reﬂect local
management practices and ESRD outcomes. Country-
speciﬁc costs were derived from published sources. A 25-
year time horizon was used. Mean total lifetime costs
(TC) and life expectancy (LE) were calculated for patients
with baseline age 59 years (mean age of the IDNT pop-
ulation). Future costs and beneﬁts were discounted at 3%
p.a. Sensitivity analysis was performed to identify 
parameters with an important impact, and to assess the
effect of varying key assumptions on the robustness of 
the model. RESULTS: In Belgium, irbesartan lead to
improved LE of 0.62 years and 0.42 years, and projected
25 year TC savings of €11,776 and €20,132/patient
versus no treatment or amlodipine respectively. In France,
improvements in LE were similar, but cost savings were
greater (TC savings of €14,382 and €23,249 versus
placebo or amlodipine respectively). The results were
robust under a wide range of plausible assumptions.
CONCLUSIONS: Treating hypertensive type 2 diabetes
patients with nephropathy using irbesartan was both
cost- and life-saving compared to amlodipine or antihy-
pertensive therapy alone.
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OBJECTIVE: Comparing a ﬁxed combination of an
ACE-inhibitor and a Non-Dihydropyridine-Calcium-
Channel-Blocker (trandolapril/verapamil) with other
medications in the treatment of hypertensive type-2 dia-
betics to determine medical consequences of a beneﬁcial
metabolic effect as judged by HbA1c value. METHODS:
A computer model was developed in order to assess long-
term effects of various levels of HbA1c on diabetes-
related complications for hypertensive patients with
diabetes type-2, who were treated with ﬁxed antihyper-
tensive combinations. Data from 2 clinical studies were
extrapolated to 10 years. The expected event rate was 
calculated per treatment group, based on UKPDS data.
Complications included in the model: renal failure, pho-
tocoagulation, vitreous hemorrhage, blindness, cataract
extraction, amputation, myocardial infarction, angina,
547Abstracts
heart failure, and non-fatal stroke. RESULTS: The
ACE/CCB-combination showed a beneﬁcial effect on
HbA1c values, and the resulting event rate in this group
is lower than for patients treated with ﬁxed combinations
like atenolol/chlorthalidone or enalapril/hydrochloroth-
iazide. Extrapolating data from one study, the relative
risk was lowered by 20% for most diabetes-related events
in comparison to atenolol/chlorthalidone. “Cataract
extraction” and “renal failure” were reduced by 19%,
“blindness” by 30%. The risk reduction for CVD
amounted 13% for non-fatal myocardial infarction, 12%
for non-fatal stroke. In the second study, the relative 
risk for “Cataract extraction” is reduced by 16% in 
the ACE/CCB-group after 10 years, compared to the 
patient group treated with a combination enalapril/
hydrochlorothiazide. The risk reduction for CVD
amounted 17% for non-fatal myocardial infarction and
16% for non-fatal stroke. CONCLUSION: The use of
this computerized model allows gaining insight into the
long-term medical outcomes of the treatment with ACE/
CCB-combination in hypertensive type-2 diabetics. The
model shows a beneﬁcial effect for the combination 
trandolapril/verapamil in diabetic patients because of the
additional HbA1c decreasing effect beside the hyperten-
sion management.
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OBJECTIVE: The primary objective is to evaluate the
clinical and economic outcomes of monotherapy with a
sulfonylurea versus dual therapy with metformin and a
sulfonylurea in a county health care system. METHODS:
This is a retrospective, chart-review, study in which the
patients will serve as their own controls, prior to starting
dual therapy. All patients are evaluated two years prior
to and post the addition of the second agent, metformin.
Data collected will include the following: HbA1C, fasting
blood glucose, lipid proﬁle, and liver and renal function
tests, adverse drug reactions, number of hospital and
emergency room admissions, number and type of clinic
visits, and number of operations/procedures/and diag-
nostic tests. The t-test for paired data is utilized to analyze
the continuous variables. RESULTS: A total of 124
patients enrolled in this study, with a mean duration of
diabetes of 6.68 years (SD 4.62). The average HbA1c on
monotherapy is 10.5% versus 10.2% on dual therapy
(NS). The average fasting blood glucose is 229mg/dL 
on monotherapy versus 192mg/dL on dual therapy 
(p < 0.05). For the economic outcomes on monotherapy
there is an average of 1.31 visits per patient versus 1.43
visits on dual therapy to the emergency room, hospital,
and to ambulatory care clinics. On monotherapy, 31% of
the patients had procedures and 37% had diagnostic
tests, compared to 38% and 51% respectively, on dual
therapy. CONCLUSIONS: This study does point to better
clinical outcomes with dual therapy; however, there is a
concurrent rise in the resource utilization. This increase
could be due to more education on the physician side 
for preventive practices and to an increase in the patient
access within the system. More research, especially
prospectively designed studies, need to be conducted to
determine the exact clinical and economic impact of dual
oral therapy for diabetes.
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OBJECTIVE: Implementing an internet-based managed
care model for diabetes care in Switzerland. METHODS:
The CareCard Diabetes is a national standard for diabetes
care in Switzerland. In a joint approach the largest Swiss
health insurance and an urban general practitioners’ asso-
ciation have launched a joint quality assurance initiative
for diabetes care in Luzern. An Internet quality assurance
database is used to connect the physicians. Data from the
CareCard were supplemented with speciﬁc anamnestic
data and information regarding diabetes medication in
order to allow for cost-effectiveness and risk analyses.
The data are presented to the physician in several ways.
Most important is a weighted problem list as a feedback
to the GP, which gives advice on how to improve the dia-
betes care for each patient. The diabetic has access to the
online CareCard Diabetes and via web-interface or call-
center, and the entry of self-control data is possible. The
physician in return has access to the self-control data of
the patient and can derive information for the optimisa-
tion of the therapy. Quality campaigns help to facilitate
the use of the system and to promote widely accepted
guideline knowledge into routine diabetes care. A proof-
of-concept study in Luzern has started in June 2001, with
currently 176 patients being enrolled. RESULTS: HbA1c
values decreased in type 2 diabetes patients from 7.3%
to 6.9% (p < 0.05). Men initially had worse HbA1c levels
and showed greater improvements -0.5% than women
did -0.2% (p < 0.05). Results from an additional HbA1c
quality assurance campaign found a relevant deviation of
practice measured HbA1c levels (mean 6.9 % +/- 1.4%)
in comparison to reference laboratory measurements
(mean 7.3 % +/- 1.4%). The study will end in June 2003.
